Seoul St. Mary's Hospital Selected for ‘Korea-U.S. Innovation Outcome Creation R&D’ for Second Consecutive Year
Professor Seunggi Kwak's team to develop targeted therapies for rheumatoid arthritis and inflammatory bowel disease
Development of small-molecule and nanobody-based candidates targeting IL-6 and IL-23
Up to KRW 7 billion in funding through 2028
Seoul St. Mary's Hospital has been selected for the ‘Korea-U.S. Innovation Outcome Creation R&D Project’ supervised by the Ministry of Health and Welfare for the second consecutive year.
On August 20, Seoul St. Mary's Hospital announced that the research team led by Professor Seunggi Kwak, Head of the Hematology and Immunology Disease Platform Center, was selected for the same project in 2026, following the selection of Professor Ji Hyun Joo, Head of the Precision Regenerative Medicine Platform Center, in 2025.
Seungki Kwak, Professor of Rheumatology at Seoul St. Mary's Hospital. Seoul St. Mary's Hospital
View original imageThis project aims to support international joint research between domestic research-driven hospitals and U.S. research institutions, promoting the globalization of outstanding research outcomes and the acquisition of advanced technologies. Professor Kwak’s team will receive up to KRW 7 billion in research funding over three years by the end of 2028.
Professor Kwak’s team will pursue the development of a next-generation therapy that simultaneously targets IL-6 and IL-23, which are key inflammatory signals in rheumatoid arthritis and inflammatory bowel disease.
The research team plans to differentiate from existing biologics—mainly injection medications—by developing small-molecule oral drugs, nanobody-based therapies, and candidates in which drugs are conjugated with nanobodies. Through this, they aim to establish a treatment strategy that selectively acts on disease-related targets.
This study involves the domestic biotechnology company Interon Korea, the College of Pharmacy at Seoul National University, and Harvard Medical School in the United States. Interon Korea will be responsible for identifying therapeutic candidates, Harvard Medical School will focus on the discovery and optimization of nanobodies, and the College of Pharmacy at Seoul National University will lead druggable design for the candidates. Seoul St. Mary's Hospital will verify the efficacy and safety of the candidate substances using patient-derived tissues and animal testing.
After evaluating the efficacy, safety, and tolerability of the candidate substances, the research team plans to promote commercialization through technology transfer or joint development.
Professor Kwak stated, “Patients with rheumatoid arthritis or inflammatory bowel disease often experience the burden of repeated injections and a decrease in therapeutic efficacy. Through this international joint research, we are focusing on developing new therapies that can improve patient convenience and quality of life.”
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Professor Myungshin Kim, Vice President for Research, added, “We are strengthening our research capabilities to continuously participate in large-scale national international collaborative research projects using our research platform. We are also enhancing the research and development system that connects basic research, translational research, clinical trials, and technology commercialization.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.